Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | MMP7 | P09237 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941806 | 1.00 | MMP1 (0.41) | MMP1MMP3MMP7MMP2HDAC8 | |
| SCHEMBL4943086 | 0.89 | MMP1 (0.44) | MMP1MMP3MMP7HDAC8MMP13 | |
| SCHEMBL4943089 | 0.89 | MMP1 (0.44) | MMP1MMP3MMP7HDAC8MMP13 | |
| SCHEMBL7215367 | 0.88 | ATM (0.38) | MMP1MMP3MMP7MMP13AGTR2 | |
| SCHEMBL4949464 | 0.84 | OPRK1 (0.46) | ALDH1A1OPRM1OPRK1KDM1A | |
| SCHEMBL4949451 | 0.84 | OPRK1 (0.46) | ALDH1A1OPRM1OPRK1KDM1A | |
| SCHEMBL20741005 | 0.80 | KLK7 (0.44) | MMP1MMP3MMP7HDAC8MMP13 | |
| SCHEMBL20741003 | 0.80 | KLK7 (0.44) | MMP1MMP3MMP7HDAC8MMP13 | |
| SCHEMBL19209005 | 0.80 | KLK7 (0.44) | MMP1MMP3MMP7HDAC8MMP13 | |
| SCHEMBL4936035 | 0.80 | MMP1 (0.36) | MMP1MMP3MMP7MMP2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| EP-1390347-B1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| US-7115639-B2 | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| EP-1268419-B1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | MERCK SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | MMP1 4697/4885MMP3 4269/4885MMP7 2738/4885 |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | MMP1 4703/4885MMP3 4253/4885MMP7 2409/4885 |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | OXTR, PRLHR, PGF | MMP1 3569/4885MMP3 2045/4885MMP7 3322/4885 |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | OXTR, PRLHR, OXER1 | MMP1 4151/4885MMP3 2263/4885MMP7 3631/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | MMP1 4354/4885MMP3 4717/4885MMP7 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.